Mid-Infrared interferometry of dust around massive evolved stars

We report long-baseline interferometric measurements of circumstellar dust around massive evolved stars with the MIDI instrument on the Very Large Telescope Interferometer and provide spectrally dispersed visibilities in the 8-13 micron wavelength band. We also present diffraction-limited observations at 10.7 micron on the Keck Telescope with baselines up to 8.7 m which explore larger scale structure. We have resolved the dust shells around the late type WC stars WR 106 and WR 95, and the enigmatic NaSt1 (formerly WR 122), suspected to have recently evolved from a Luminous Blue Variable (LBV) stage. For AG Car, the protoypical LBV in our sample, we marginally resolve structure close to the star, distinct from the well-studied detached nebula. The dust shells around the two WC stars show fairly constant size in the 8-13 micron MIDI band, with gaussian half-widths of ~ 25 to 40 mas. The compact dust we detect around NaSt1 and AG Car favors recent or ongoing dust formation. Using the measured visibilities, we build spherically symmetric radiative transfer models of the WC dust shells which enable detailed comparison with existing SED-based models. Our results indicate that the inner radii of the shells are within a few tens of AU from the stars. In addition, our models favor grain size distributions with large (~ 1 micron) dust grains. This proximity of the inner dust to the hot central star emphasizes the difficulty faced by current theories in forming dust in the hostile environment around WR stars. Although we detect no direct evidence for binarity for these objects, dust production in a colliding-wind interface in a binary system is a feasible mechanism in WR systems under these conditions.Comment: 21 pages, 4 tables, 13 figures. Accepted for publication in the Astrophysical Journa

Bolometric luminosity variations in the Luminous Blue Variable AFGL2298

We characterise the variability in the physical properties of the luminous blue variable AFGL2298 between 1989-2008. In conjunction with published data from 1989-2001, we have undertaken a long term (2001-2008) near-IR spectroscopic and photometric observational campaign for this star and utilise a non-LTE model atmosphere code to interpret these data. We find AFGL2298 to have been highly variable during the two decades covered by the observational datasets. Photometric variations of >1.6 mag have been observed in the JHK wavebands; however, these are not accompanied by correlated changes in near-IR colour. Non-LTE model atmosphere analysis of 4 epochs of K band spectroscopy obtained between 2001-7 suggests that the photometric changes were driven by expansion and contraction of the stellar photosphere accompanied by comparatively small changes in the stellar temperature. Unclumped mass loss rates throughout this period were modest and directly comparable to those of other highly luminous LBVs. However, the bolometric luminosity of AFGL2298 appears to have varied by at least a factor of ~2 between 1989-2008, with it being one of the most luminous stars in the Galaxy during maximum. Comparison to other LBVs that have undergone non bolometric luminosity conserving `eruptions' shows such events to be heterogeneous, with AFGL2298 the least extreme example. These results - and the diverse nature of both the quiescent LBVs and associated ejecta - may offer support to the suggestion that more than one physical mechanism is responsible for such behaviour. [ABRIDGED]Comment: 12 pages, 6 figures, accepted for publication in Astronomy and Astrophysic

Diastolic function measurements and diagnostic consequences: a comparison of pulsed wave- and color-coded tissue Doppler imaging

Tissue Doppler imaging (TDI) plays an important role in assessing diastolic function using echocardiography. However, two different methods [pulsed wave (PW-TDI) and color-coded (CC-TDI)] are currently used. We aimed to compare both measurements. We included 114 patients that were referred to our echocardiography department for evaluation of diastolic left ventricular function. In these patients, we sequentially measured tissue velocities of basal lateral and septal myocardium of the left ventricle in an apical four-chamber view with both PW-TDI and CC-TDI. Our cohort consisted of a heterogeneous group of patients with and without a history of cardiac disease. Mean age of the patients was 52 +/- A 16.7 years, and 62% were males. We found a strong correlation between PW-TDI- and CC-TDI-derived myocardial velocities (r = 0.93; p = 0.001). However, E' (mean of lateral and septal) velocities measured with PW-TDI were consistently higher compared to CC-TDI values [PW-TDI E' 10.3 +/- A 3.9 (SD) cm/s vs. CC-TDI E' 7.7 +/- A 3.1 cm/s; p <0.001]. From these data, we calculated that the relation between E' measured with PW-TDI and CC-TDI can be described as: E' (PW-TDI) = 1.25 + 1.17 x E' (CC-TDI). Consequently, E/E' measured with PW-TDI was consistently lower compared with CC-TDI (9.1 +/- A 3.1 vs. 12.5 +/- A 5.7; p <0.001) From these data, we calculated that the relation between E/E' measured with PW-TDI and CC-TDI can be described as: E/E' (PW-TDI) = 2.13 + 0.56 x E/E' (CC-TDI). Despite a strong correlation, tissue velocities measured with PW-TDI will yield higher values as compared with CC-TDI. This should be taken into account when defining cut-off values for the evaluation of diastolic function

Reference material for radionuclides in sediment IAEA-384 (Fangataufa Lagoon sediment)

Author Posting. © Springer, 2007. This is the author's version of the work. It is posted here by permission of Springer for personal use, not for redistribution. The definitive version was published in Journal of Radioanalytical and Nuclear Chemistry 273 (2007): 383-393, doi:10.1007/s10967-007-6898-4.A reference material designed for the determination of anthropogenic and natural radionuclides in sediment, IAEA-384 (Fangataufa Lagoon sediment), is described and the results of certification are presented. The material has been certified for 8 radionuclides (40K, 60Co, 155Eu, 230Th, 238U, 238Pu, 239+240Pu and 241Am). Information values are given for 12 radionuclides (90Sr, 137Cs, 210Pb (210Po), 226Ra, 228Ra, 232Th, 234U, 235U, 239Pu, 240Pu and 241Pu). Less reported radionuclides include 228Th, 236U, 239Np and 242Pu. The reference material may be used for quality management of radioanalytical laboratories engaged in the analysis of radionuclides in the environment, as well as for the development and validation of analytical methods and for training purposes. The material is available from IAEA in 100 g units

The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department

The hypothalamic-pituitary-adrenal axis is activated in response to stress. One of the activated hypothalamic hormones is arginine vasopressin, a hormone involved in hemodynamics and osmoregulation. Copeptin, the C-terminal part of the arginine vasopressin precursor peptide, is a sensitive and stable surrogate marker for arginine vasopressin release. Measurement of copeptin levels has been shown to be useful in a variety of clinical scenarios, particularly as a prognostic marker in patients with acute diseases such as lower respiratory tract infection, heart disease and stroke. The measurement of copeptin levels may provide crucial information for risk stratification in a variety of clinical situations. As such, the emergency department appears to be the ideal setting for its potential use. This review summarizes the recent progress towards determining the prognostic and diagnostic value of copeptin in the emergency department

Giving is a question of time: Response times and contributions to a real world public good

Recent experimental research has examined whether contributions to public goods can be traced back to intuitive or deliberative decision-making, using response times in public good games in order to identify the specific decision process at work. In light of conflicting results, this paper reports on an analysis of response time data from an online experiment in which over 3400 subjects from the general population decided whether to contribute to a real world public good. The between-subjects evidence confirms a strong positive link between contributing and deliberation and between free-riding and intuition. The average response time of contributors is 40 percent higher than that of free-riders. A within-subject analysis reveals that for a given individual, contributing significantly increases and free-riding significantly decreases the amount of deliberation required

Reference Material for Radionuclides in Sediment, IAEA-384 (Fangataufa Lagoon Sediment)

The IAEA Marine Environment Laboratory (IAEA-MEL) in Monaco has conducted intercomparison exercises on radionuclides in marine samples for many years as part of its contribution to the IAEA's program of Analytical Quality Control Services (AQCS). An important part of the AQCS program has been a production of Reference Materials (RMs) and their provision to radioanalytical laboratories. The RMs have been developed for different marine matrices (sediment, water, biota), with accuracy and precision required for the present state of the art of radiometrics and mass spectrometry methods. The RMs have been produced as the final products of world-wide intercomparison exercises organized during last 30 years. A total of 44 intercomparison exercises were undertaken and 39 RMs were produced for radionuclides in the marine environment. All required matrices (seawater, biota, sediment) have been covered with radionuclide concentrations ranging from typical environmental levels to elevated levels affected by discharges from nuclear reprocessing plants. The long-term availability of RMs (over 10 years) requires the use of very specific techniques to collect and pretreat large quantities of material (e.g., in excess of 100 kg) in order to ensure sample stability and homogenization of any analytes of interest. The production of a RM is therefore a long process, covering the identification of needs, sample collection, pre-treatment, homogenization, bottling, distribution to laboratories, evaluation of data, preliminary reporting, additional analyses in expert laboratories, certification of the material, and finally issuing the RM. In this paper we describe a reference material IAEA-384, Fangataufa lagoon sediment, designed for determination of anthropogenic and natural radionuclides in the marine environment. This RM has been prepared with the aim of testing the performance of analytical laboratories to measure the activity of these radionuclides in a sediment sample contaminated by elevated levels of fallout from nuclear weapons tests. Participating laboratories were requested to determine as many radionuclides as possible by radiometric (alpha, beta and gamma-spectrometry) as well as by mass spectrometry methods (e.g., ICPMS - Inductively Coupled Plasma Mass Spectrometry, TIMS - Thermal Ionization Mass Spectrometry, AMS - Accelerator Mass Spectrometry)

Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

&lt;p&gt;Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.&lt;/p&gt; &lt;p&gt;Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate &#60;60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.&lt;/p&gt; &lt;p&gt;Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.&lt;/p&gt

Erythropoietin in the intensive care unit: beyond treatment of anemia

Erythropoietin (EPO) is the major hormone stimulating the production and differentiation of red blood cells. EPO is used widely for treating anemia of critical illness or anemia induced by chemotherapy. EPO at pharmacological doses is used in this setting to raise hemoglobin levels (by preventing the apoptosis of erythroid progenitor cells) and is designed to reduce patient exposure to allogenic blood through transfusions. Stroke, heart failure, and acute kidney injury are a frequently encountered clinical problem. Unfortunately, in the intensive care unit advances in supportive interventions have done little to reduce the high mortality associated with these conditions. Tissue protection with EPO at high, nonpharmacological doses after injury has been found in the brain, heart, and kidney of several animal models. It is now well known that EPO has anti-apoptotic effects in cells other than erythroid progenitor cells, which is considered to be independent of EPOs erythropoietic activities. This review article summarizes what is known in preclinical models of critical illness and discusses why this does not correlate with randomized, controlled clinical trials

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.